Results 31 to 40 of about 1,472 (172)

Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for Clostridioides difficile Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective

Antibiotics, 2021
Introduction: Approximately 3% of hospitalized patients with community-acquired bacterial pneumonia (CABP) develop healthcare-associated Clostridioides difficile infection (HCA-CDI). The validated Davis risk score (DRS) indicates that patients with a DRS
Thomas Lodise, Mauricio Rodriguez, Surya Chitra, Kelly Wright, Nimish Patel   +4 more
doaj   +1 more source

Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline [PDF]

Clinical Infectious Diseases, 2019
AbstractOral and intravenous (IV) omadacycline formulations are approved in the United States for treating acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in adults. Oral omadacycline bioavailability is 34.5%; similar exposures are obtained following 300 mg oral and 100 mg IV doses.
Rodvold, Keith A, Pai, Manjunath P
openaire   +2 more sources

Omadacycline: a novel aminomethylcycline.

Infection and drug resistance, 2019
Tetracyclines have come a long way since they became available almost seven decades ago, with numerous enhancements allowing new agents to overcome bacterial mechanisms of resistance. However, these enhancements come with toxicities and pharmacokinetic disadvantages such as the gastrointestinal side-effects and poor oral bioavailability seen with the ...
Burgos,Rodrigo M, Rodvold,Keith A
openaire   +5 more sources

Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia

International Journal of Infectious Diseases, 2021
Objective: Community-acquired bacterial pneumonia (CABP) is a major clinical burden worldwide. In the phase III OPTIC study (NCT02531438) in CABP, omadacycline was found to be non-inferior to moxifloxacin for investigator-assessed clinical response (IACR)
Antoni Torres, Lynne Garrity-Ryan, Courtney Kirsch, Judith N. Steenbergen, Paul B. Eckburg, Anita F. Das, Marla Curran, Amy Manley, Evan Tzanis, Paul C. McGovern   +9 more
doaj   +1 more source

AdeABC Efflux Pump Controlled by AdeRS Two Component System Conferring Resistance to Tigecycline, Omadacycline and Eravacycline in Clinical Carbapenem Resistant Acinetobacter nosocomialis

Frontiers in Microbiology, 2020
Carbapenem-resistant Acinetobacter nosocomialis (CRAn) is a significant public health concern. Tigecycline non-susceptible CRAn (Tn-CRAn) isolates have emerged worldwide.
Yi-Tzu Lee, Yi-Tzu Lee, Hsing-Yu Chen, Ya-Sung Yang, Yu-Ching Chou, Tein-Yao Chang, Wei-Jane Hsu, I-Chieh Lin, ACTION Study Group, Jun-Ren Sun   +9 more
doaj   +1 more source

Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of M. abscessus lung disease

mSphere
Treatment outcomes for Mycobacteroides abscessus (Mab, also known as Mycobacterium abscessus) disease are still unsatisfactory, mainly due to issues with drug toxicity, tolerability, and efficacy.
Elisa H. Ignatius, Binayak Rimal, Chandra M. Panthi, Daniel C. Belz, Christopher K. Lippincott, Daniel H. Deck, Alisa W. Serio, Gyanu Lamichhane   +7 more
doaj   +1 more source

Empiric treatment approach for the management of post-operative incisional infections with omadacycline

Foot & Ankle Surgery: Techniques, Reports & Cases, 2023
: Background: Surgical wound dehiscence (SWD) is one of the most common complications of surgical incision sites after foot surgeries because of blood flow and circulation issues that may occur in the foot. Such SWD complications can potentially lead to
Philip Wrotslavsky
doaj   +1 more source

Omadacycline Enters the Ring: A New Antimicrobial Contender [PDF]

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
Omadacycline is a novel aminomethylcycline approved for the treatment of community‐acquired bacterial pneumonia and acute bacterial skin and skin structure infections. This article reviews existing data pertaining to the biochemistry, mechanism of action, pharmacokinetics/pharmacodynamics, in vitro activity, and current progress with omadacycline in ...
Katie E. Barber, Alison M. Bell, Mary Joyce B. Wingler, Jamie L. Wagner, Kayla R. Stover   +4 more
openaire   +2 more sources

Mechanism of Action of the Novel Aminomethylcycline Antibiotic Omadacycline [PDF]

Antimicrobial Agents and Chemotherapy, 2014
ABSTRACT Omadacycline is a novel first-in-class aminomethylcycline with potent activity against important skin and pneumonia pathogens, including community-acquired methicillin-resistant Staphylococcus aureus (MRSA), β-hemolytic streptococci, penicillin-resistant Streptococcus pneumoniae
Michael P, Draper, S, Weir, A, Macone, J, Donatelli, C A, Trieber, S K, Tanaka, Stuart B, Levy   +6 more
openaire   +2 more sources

Case Report: Omadacycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in an adolescent patient

Frontiers in Cellular and Infection Microbiology, 2023
Omadacycline is a novel tetracycline antibiotic that exhibits good in vitro antibacterial activity against atypical pathogens such as Mycoplasma pneumoniae. It is approved for the treatment of adults with community-acquired bacterial pneumonia.
Limin Xu, Changquan Fang
doaj   +1 more source